MRNA Moderna, Inc.
Moderna, Inc. (MRNA) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $1.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +243.8% since its last earnings release on July 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Moderna, Inc.
Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale.
Sector
Healthcare
Industry
Biotechnology
Held By 14 ETFs, by dollar flow
- BUZZ Vaneck Social Sentiment ETF
- BUZZ Vaneck Social Sentiment ETF
- XT iShares Exponential Technologies ETF
- XT iShares Exponential Technologies ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- XLV Health Care Select Sector SPDR Fund
- XLV Health Care Select Sector SPDR Fund
- IXJ iShares Global Healthcare ETF
- IXJ iShares Global Healthcare ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
- IDNA iShares Genomics Immunology and Healthcare ETF
- IDNA iShares Genomics Immunology and Healthcare ETF
Charts powered in part by Lightweight Charts™ by TradingView.